NCT05316922 (WIN-HYPO2021) is a Phase 3 clinical trial of Levothyroxine in Hypothyroidism; Irradiation, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

Who is sponsoring NCT05316922?

NCT05316922 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

What drugs are being tested in NCT05316922?

Interventions in NCT05316922: Levothyroxine.

What condition does NCT05316922 study?

NCT05316922 studies Hypothyroidism; Irradiation.

Is NCT05316922 still recruiting?

NCT05316922 is currently recruiting now. Last updated 6 December 2023.

Last reviewed 2023-12-06 · How we verify

NCT05316922: WIN-HYPO2021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients

Recruiting now Phase 3 Last updated 6 December 2023

What this trial tests

Phase 3 trial testing Levothyroxine in Hypothyroidism; Irradiation in 68 participants. Currently enrolling.

Timeline

13 December 2021

Primary endpoint
30 September 2029

30 September 2029

Quick facts

Lead sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	68
Start date	13 December 2021
Primary completion	30 September 2029
Estimated completion	30 September 2029
Sites	1 location across Italy

Drugs / interventions tested

Levothyroxine (levothyroxine) — full drug profile →

Conditions studied

Hypothyroidism; Irradiation — all drugs for Hypothyroidism; Irradiation →

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →

Who can join

Eligibility, any sex, with Hypothyroidism; Irradiation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To offer the possibility of a treatment that could achieve a meaningful reduction in the incidence of post-radiation therapy hypothyroidism. Thyroid dysfunction may develop from a few months to several years after patients have completed their radiation treatment. In children with chronic diseases, or given lengthy anti-neoplastic treatments, recurrent or persistent endocrine disorders may have a negative effect on growth and development into adulthood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levothyroxine

Trials testing the same drug.

NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism · Phase 2, PHASE3 · recruiting
NCT06625814 — A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) · Phase 1 · completed
NCT06428097 — Levothyroxine Supplementation for Heart Transplant Recipients · Phase 1 · recruiting
NCT05712421 — A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in P · Phase 2 · completed
NCT05412979 — A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Pati · Phase 2 · completed

Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials

Trials by the same sponsor.

NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
NCT06999824 — Revisiting the Concept of Nerve Sparing Radical Hysterectomy · not yet recruiting
NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05316922 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Last refreshed: 6 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05316922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing